ExplainersBiometric wearables
Biometric wearables
Biometric-primary + AI-augmented devices. The framework applies FDA-clearance-as-verification (ECG/AFib cleared; Body Battery + Strain/Recovery + Readiness wellness-grade) and the Whoop vs Oura verified-vs-claimed exemplar pair.
19 explainers
The biometric cohort is the conscious axis-extension parallel to how wearable form_factor was created. Where AI wearables is AI-substance-spectrum-centric (genuine cloud AI vs moderate open-source vs partner-mediated vs veneer), biometric is biometric-primary + AI-augmented. The boundary test: would these devices exist without the AI layer? For biometric (Apple Watch + Pixel Watch + Fitbit + Whoop + Withings + Samsung + Garmin + Oura + RingConn + Ultrahuman + Zepp Health/Amazfit + Movano + Dexcom Stelo), yes-but-degraded; the AI layer adds insights to a hardware-primary sensor-recording product. For AI wearables, no-the-AI-is-the-product. The cohort split surfaces a distinct framework.
The framework anchor is FDA-clearance-as-verification. Only ECG/AFib is genuinely cleared across the cohort: Apple Watch + Pixel Watch + Fitbit + Withings + Samsung carry substantial clearance breadth; Garmin + Whoop carry lighter ECG-only clearance. Body Battery, Strain/Recovery, Readiness, Healthspan, SpO2 trends, sleep scores, and Samsung's US BP feature all sit at wellness-grade, not medical-device tier. The cardiologist-validation gradient is verification posture, not editorial judgment; the framework reads cleared features at one tier and wellness-grade features at another.
The Whoop vs Oura verified-vs-claimed exemplar pair is the cohort's sharpest editorial framing. Whoop marketed Blood Pressure Insights without FDA clearance, drew an FDA Warning Letter July 14 2025, refused removal, and was unresolved as of May 2026 alongside a class action. Oura ran a December 2025 BP study before marketing any BP feature: study-first vs market-first contrast. The contrast is structural, not just brand commentary; it surfaces what verification-posture discipline looks like across competing claim patterns.
Cohort architecture: form-factor splits (rings Oura + RingConn + Ultrahuman + Movano; watches Apple + Pixel + Fitbit + Withings + Samsung + Garmin; bands Whoop + Zepp Health/Amazfit; glucose sensors Dexcom Stelo) intersect with subscription-model spectrum (Whoop subscription-only; Oura purchase + required; Fitbit + Withings + Pixel purchase + optional; Garmin + Apple + Samsung purchase-only) and FDA-clearance posture (substantial cleared vs lighter cleared vs general-wellness). Dexcom Stelo is the medical-sensor-with-AI-insight bridge cell (Vertex AI / Gemini integration), distinct from the general biometric tier.
The biometric cluster carries fourteen entity-anchor explainers covering full cohort breadth matching Agent B's /price depth. Foundational nine (Wave 1 + 2): the Whoop Blood Pressure Insights FDA Warning Letter (within-feature dispute archetype); Oura Ring 4 (study-first archetype + Whoop exemplar-pair partner); Apple Watch (substantial-cleared archetype + cohort canonical reference); Pixel Watch 3 (first-of-kind-cleared archetype); Fitbit (budget-tier cleared archetype with strongest validation-at-price-point gradient); Dexcom Stelo (glucose-biometric cell generative AI substance anchor); Withings ScanWatch (hybrid analog watch archetype); Garmin (lighter-cleared archetype + athletics-primary positioning); Samsung Galaxy Watch (Korean-headquartered cohort entrant with Korea + EU vs US clearance gradient). Wave 3 five (just shipped): RingConn (Gen 2 / Gen 3) (subscription-free ring; AHI 90.7%-claimed but NOT FDA-cleared; ITC settled-licensed NOT banned); Ultrahuman Ring (Air / Pro) (market-access-redesigned archetype; US blocked Oct 21 2025 → restored Mar 24 2026 via Ring Pro unibody redesign; AFib via FibriCheck third-party); Happy Ring (FDA-cleared + service-gated archetype; dual K240236 + K242224 clearances; sharp within-cohort verified-vs-claimed counterpoint to RingConn AHI claims); Abbott Lingo (adaptive-algorithmic glucose biometric; FDA K233655 May 2024; paired with Stelo's generative AI substance documents within-cell AI-substance gradient); Whoop full-entity anchor (subscription-only band cohort exemplar; ~$478 Year 1; $10.1B Series G March 2026 lead Collaborative Fund CORRECTED from QIA/Mubadala; BP Insights dispute UNRESOLVED May 2026). Remaining biometric entity-anchor explainers (Movano post-Corvex-reverse-merger lifecycle-flip + Zepp Health/Amazfit) ship across upcoming waves. Per-entity registry institutional depth lives at the registry's /companies + /models surfaces (no /biometric category page exists on either property as of mid-2026; route to constituent entities).
For the framework canonical reference + canonical worked examples demonstrating the discipline operationally, see how DEPLOY verifies. For the canonical category umbrella that includes biometric devices alongside AI wearables and the other physical AI cohorts, see what is physical AI.
For methodology pillar canonical references applicable to the biometric cohort: verified-vs-claimed at within-entity granularity (CANONICAL: Apple Watch SpO2 cleared-vs-wellness-only + Whoop BPI sleep-cleared-vs-Warning-Letter-blood-pressure as the canonical within-entity worked examples); the 9-tier source-quality rubric (FDA + CPSC + ITC primary-government-record + per-claim source classification across biometric incident + clearance claims).
Adjacent clusters
- AI wearables: Boundary-adjacent cohort: AI wearables (AI-substance spectrum centric) vs biometric (biometric-primary + AI-augmented). The conscious axis-extension parallel surfaces what makes each cohort editorially distinct.
- Surgical robotics: FDA-clearance discipline parallel: the framework applies symmetrically across surgical (FDA-clearance-as-gating-event for surgical autonomy claims) and biometric (FDA-clearance-as-verification for cardiac claims). Categories differ; discipline does not.
Featured
What is Oura Ring 4?
Oura is a Finnish-founded biometric wearable company headquartered in Oulu and San Francisco; the Oura Ring 4 (current generation) is the cohort's study-first verification posture archetype. Where Whoop shipped Blood Pressure Insights in May 2025 without published clinical-validation study and drew an FDA Warning Letter, Oura ran a December 2025 BP study before any consumer BP feature shipped. Pricing: $349 outright + $5.99/month Oura Membership OR ~$400 lifetime membership. FDA posture: general-wellness only (no specific medical clearances); deepest peer-reviewed sleep validation in cohort. October 2025 funding round at $11B valuation positions Oura as Whoop's economic peer at opposite verification posture.
Read →
What is Whoop?
Whoop is a subscription-only fitness + recovery biometric band, positioned within the biometric cluster as the subscription-only band cohort exemplar. $239 hardware + $239/yr subscription = ~$478 Year 1 effective cost (subscription-only model; hardware-cost subsidized). $10.1B Series G March 2026 lead Collaborative Fund (CORRECTED from earlier aggregator-quoted QIA/Mubadala framing per Agent A re-verify). BP Insights 'not for hypertension diagnosis' manufacturer framing vs FDA July 14, 2025 Warning Letter; class action late 2025/early 2026; dispute still UNRESOLVED as of May 2026 per Agent A re-verify. Editorial throughline: subscription-only band cohort exemplar + manufacturer-position-vs-FDA-position editorial framing (same framing as existing Whoop BP Warning Letter feature explainer, but applied at full-entity scope; full entity anchor surfaces commercial model + product features + funding state + FDA dispute as integrated context).
Read →
What is Happy Ring?
Happy Ring is a service-gated FDA-cleared smart ring biometric from Happy Health. Per Agent A Wave 3 biometric ingest: TWO dated FDA 510(k) clearances anchor the verification posture: K240236 (October 8, 2024, remote monitoring; NOT 'screening' per Agent A correction) + K242224 (June 18, 2025, home sleep test diagnosis support, ages 22+, clinician-directed; NOT autonomous diagnosis per Agent A correction). Service-gated availability: sold only bundled into insurer-billed Happy Sleep service (NO retail price; honest-absence on consumer pricing). $60M Series A August 2022; commercially active across 48 states with OpenLoop + EnsoData service infrastructure (CORRECTED from earlier 'quiet since 2022' framing per Agent A re-verify sweep). 97% PSG agreement company-reported (no peer-reviewed citation per Agent A). 'Brain biometrics' marketing UNSUBSTANTIATED by named EEG hardware (cap-flag explicitly). Editorial throughline: sharp within-cohort verified-vs-claimed counterpoint to RingConn AHI claims (same form factor + similar capability claims + diametrically opposite verification posture).
Read →
What is Dexcom Stelo?
Dexcom Stelo is the first OTC continuous glucose monitor (CGM) for non-diabetic consumers, cleared via FDA De Novo pathway March 2024. Stelo carries Dexcom's medical-sensor heritage + a Vertex AI / Gemini generative AI insight layer that distinguishes it from Abbott Lingo's adaptive algorithmic AI substance. Pricing: ~$89 per 2-week sensor + biweekly subscription model. Per DEPLOY's biometric cluster framework, Stelo is the cohort's medical-sensor-with-AI-insight bridge cell anchor: passes biometric boundary test via genuine generative AI substance (not adaptive algorithmic) per Agent A Wave 2 + Wave 3 ingest.
Read →
All explainers in biometric wearables
How does DEPLOY track the Amazfit Helio Ring ITC investigation?
The Amazfit Helio Ring ITC investigation operates as a canonical worked example of incident-tracking at ITC patent-trade primary-source verification depth. Per Agent A IncidentStatusEvent substrate at [/incidents/amazfit-helio-ring-oura-itc-investigation-2025](https://registry.deploy.report/incidents/amazfit-helio-ring-oura-itc-investigation-2025): the U.S. International Trade Commission (ITC) is investigating the Amazfit Helio Ring (Zepp Health subsidiary product) under a Section 337 patent investigation initiated by Oura Health in 2025. The investigation operates at ITC patent-trade primary-source verification depth (tier 3 primary-government-record sub-tier per [DEPLOY's 9-tier source-quality rubric](/explainers/source-quality-rubric)); the sub-tier is structurally distinct from the CPSC consumer-product-safety sub-tier exercised in the [Fitbit Ionic burn recall narrative](/explainers/how-deploy-tracks-the-fitbit-ionic-burn-recall) + the FDA medical-device sub-tier exercised in the [Withings ScanWatch ECG recall narrative](/explainers/how-deploy-tracks-the-withings-scanwatch-ecg-recall). EDITORIAL THROUGHLINE: pairs with the broader Oura '178 patent ITC family with opposite outcomes. [Ultrahuman](/explainers/what-is-ultrahuman) excluded (US blocked Oct 21 2025 → restored Mar 24 2026 via Ring Pro unibody redesign) + [RingConn](/explainers/what-is-ringconn) licensed-and-selling (settled-licensed cleanly with Oura on '178 patent; NOT banned per Agent A correction) + now Amazfit Helio Ring under investigation operating at active-investigation verification posture. The three biometric incident narratives together demonstrate framework-in-action across regulatory-source-tier diversity within a single cohort. This piece documents the catch as framework-in-action worked example: ITC patent-trade incident-tracking discipline + active-investigation verification posture + canonical-worked-example-pair architecture compounding across the Oura ITC family operating at editorial-anchor depth.
How does DEPLOY track the Fitbit Ionic burn recall?
The Fitbit Ionic burn recall (CPSC 2022) operates as a canonical worked example of incident-tracking at primary-source verification depth. The U.S. Consumer Product Safety Commission (CPSC) issued a recall on the Fitbit Ionic smartwatch in March 2022 over reports of lithium-ion battery overheating causing burns; approximately 1 million units in the US (plus an additional ~700,000 units globally) were subject to the recall. The recall operates at CPSC primary-source verification depth (tier 3 primary-government-record per [DEPLOY's 9-tier source-quality rubric](/explainers/source-quality-rubric)); the Fitbit Ionic product line was discontinued by Fitbit as part of the recall remediation. Per [DEPLOY's biometric cluster framework](/explainers/biometric), the Ionic recall sits alongside the broader Fitbit entity scope: [Fitbit](/explainers/what-is-fitbit) anchors the budget-tier cleared archetype with strongest validation-at-price-point gradient; the Ionic incident affects a discontinued product line within the broader Fitbit portfolio. This piece documents the catch as framework-in-action worked example: incident-tracking discipline + CPSC primary-source verification + product-line discontinuation + within-entity verification-state distribution operating at editorial-anchor depth.
How does DEPLOY track the Withings ScanWatch ECG recall?
The Withings ScanWatch FDA Class-2 recall operates as a canonical worked example of incident-tracking at FDA medical-device primary-source verification depth. Per Agent A IncidentStatusEvent substrate at [/incidents/withings-scanwatch-ecg-recall-2022](https://registry.deploy.report/incidents/withings-scanwatch-ecg-recall-2022): the U.S. Food and Drug Administration (FDA) issued a Class-2 recall on the Withings ScanWatch ECG feature in 2022. The recall operates at FDA medical-device primary-source verification depth (tier 2 primary-FDA-database per [DEPLOY's 9-tier source-quality rubric](/explainers/source-quality-rubric)); the recall sub-tier is structurally distinct from the CPSC consumer-product-safety sub-tier exercised in the [Fitbit Ionic burn recall narrative](/explainers/how-deploy-tracks-the-fitbit-ionic-burn-recall). CRITICAL within-entity verification-state framing: the ScanWatch is a multi-feature device with FDA-cleared ECG + SpO2 (K201456) intersecting with the regulatory recall framing; per [verified-vs-claimed at within-entity granularity](/explainers/verified-vs-claimed-within-entity), the recall affects the ECG feature specifically while other ScanWatch features remained available; the broader [Withings entity](/explainers/what-is-withings) continues at verified-shipped state across the ScanWatch + ScanWatch 2 + ScanWatch Nova product line. Per [DEPLOY's biometric cluster framework](/explainers/biometric), the recall operates within the hybrid analog watch archetype that Withings anchors. This piece documents the catch as framework-in-action worked example: FDA medical-device incident-tracking discipline + within-entity feature-granularity verification-state distribution + multi-tier primary-government-record source-quality demonstration operating at editorial-anchor depth.
What is Abbott Lingo?
Abbott Lingo is an FDA-cleared adaptive-algorithmic glucose biometric for non-diabetic consumers, FDA 510(k) K233655 May 2024 cleared on the FreeStyle Libre 14-day glucose monitoring platform. Per Agent A Wave 3 biometric ingest: cleared for adults 18+ NOT on insulin (CAP-FLAG IMPORTANCE: distinct from Dexcom G7 which is for diabetics on insulin). ~$54/2wk price point. AI substance is 'Lingo Count' adaptive-algorithmic recommendations + rule-based integration (NOT generative); 'Lingo Live' is human nutritionists NOT AI coach (CAP-FLAG: common aggregator confusion). Editorial throughline: adaptive-algorithmic glucose biometric paired with Stelo's generative AI substance, documenting the within-cell AI-substance gradient across the glucose pair (Stelo = Vertex AI + Gemini Weekly Insights generative; Lingo = Lingo Count adaptive-algorithmic + rule-based). Cohort positioning: glucose biometric archetype within biometric cluster's glucose-cell at adaptive-algorithmic AI substance tier.
What is Apple Watch?
Apple Watch is the broadest installed-base biometric wearable in the cohort. Current product line: Apple Watch Series 10 + Apple Watch Ultra 2 + Apple Watch SE. Apple Watch operates the substantial-cleared FDA posture archetype: ECG/AFib De Novo 2018 (first consumer wearable ECG clearance), sleep apnea detection 2024, hypertension detection 2025. Purchase-only business model; no required subscription. Substantial peer-reviewed cardiologist validation (largest published study base in cohort). The Masimo blood-oxygen ITC ruling January 2024 → August 2025 redesign re-enable is a within-entity verified-vs-claimed exemplar.
What is Fitbit?
Fitbit is Google's biometric wearable product line, distinct from the Pixel Watch generation. Current product line includes Fitbit Charge 6 + Fitbit Sense + Fitbit Versa, with ECG cleared 2020 and PPG-based AFib detection cleared 2022. Google acquired Fitbit in 2021; the Premium subscription model (~$9.99/month or $79.99/year) unlocks AI-insights across both Fitbit and Pixel Watch hardware. Per DEPLOY's biometric cluster framework, Fitbit anchors the budget-tier cleared archetype: cohort's strongest cardiologist-validation-at-price-point gradient with substantive FDA portfolio at sub-$200 hardware tier.
What is Garmin?
Garmin is an American GPS technology company with substantial biometric wearable product lines including Venu + Fenix + Forerunner. ECG 510(k) cleared 2023 is currently Garmin's only cleared biometric feature; Body Battery + recovery + Pulse Ox are wellness-grade not diagnostic-cleared. Purchase-only business model (no subscription) distinguishes Garmin in cohort. Per DEPLOY's biometric cluster framework, Garmin anchors the lighter-cleared archetype: athletics-primary positioning with longest cleared-portfolio gap behind cohort canonical reference. Cap-flag: Garmin marketing extends beyond ECG 510(k) scope into Body Battery + recovery wellness-grade framings.
What is Movano Health?
[Movano Health](https://registry.deploy.report/companies/movano-health) is the operating company behind the [Evie Ring](https://registry.deploy.report/models/movano-evie-ring), a smart ring biometric positioned within the biometric cluster's ring sub-cohort. Per registry verification: company operates as Movano Health; Evie Ring is the consumer-shipped product; per [consumer surface](https://deploy.report/price/movano-evie-ring) the ring operates at consumer retail pricing tier. CRITICAL CORPORATE-STATE-SHIFT CAP-FLAG: per registry references to Corvex + reverse merger, Movano Health operates within a corporate-state-shift via reverse merger structure (verified per registry framing); specific reverse-merger mechanics + timing + post-merger entity scope + Corvex Software corporate-state-shift framing operate at lower verification posture pending primary-source confirmation. Per [DEPLOY's biometric cluster framework](/explainers/biometric), Movano Health Evie Ring operates within the ring sub-cohort alongside Oura + Whoop + RingConn + Ultrahuman + Happy Ring; specific ring-sub-cohort archetype positioning (FDA-clearance posture + subscription-model + commercial-deployment maturity) cap-flagged pending primary-source verification of Movano-specific claim depth.
What is Pixel Watch?
Pixel Watch 3 is Google's current biometric wearable generation. Per the biometric cluster framework, Pixel Watch occupies the first-of-kind-cleared FDA posture archetype: Loss-of-Pulse Detection De Novo Feb 2025 (first-of-kind consumer-wearable cardiac event detection clearance). Pixel Watch 3 at $349 (41mm) and $399 (45mm); purchase + optional Fitbit Premium subscription ($9.99/month or $79.99/year). Google parent + Fitbit product-line relationship: complementary biometric strategy under Google ownership (Pixel Watch + Fitbit form the unified biometric portfolio). Growing peer-reviewed validation (newer clearance scope than Apple Watch's 2018 ECG portfolio).
What is RingConn?
RingConn is a $279 subscription-free smart ring biometric (Gen 2 / Gen 3 variants), positioned as the subscription-free anchor within the ring sub-cohort distinct from Oura purchase+membership + Whoop subscription-only commercial models. CRITICAL CAP-FLAG per Agent A Wave 2 biometric ingest: AHI (apnea-hypopnea index) marketed at 90.7%-claimed accuracy but NOT FDA-cleared; company PR explicitly states 'actively pursuing clearance' + 'not intended to diagnose.' Sharp within-cohort verified-vs-claimed counterpoint to Happy Ring's actual K240236 + K242224 FDA clearances. ITC outcome correction per Agent A: RingConn settled-licensed cleanly with Oura on '178 patent (NOT banned; Ultrahuman was blocked). Cohort positioning: subscription-free ring archetype within biometric cluster's ring sub-cohort.
What is Samsung Galaxy Watch?
Samsung Galaxy Watch is Samsung's biometric wearable product line including Galaxy Watch 7 + Galaxy Watch Ultra + adjacent Galaxy Ring. ECG cleared 2021 + AFib detection 2023 + sleep apnea De Novo Feb 2024 (sleep apnea clearance structurally earlier than Apple Watch's later 2024 sleep apnea); cuff-calibrated BP feature cleared in Korea + EU markets but US carve-out wellness-grade. Per DEPLOY's biometric cluster framework, Samsung Galaxy Watch anchors the Korean-headquartered cohort entrant position with Korea + EU vs US clearance gradient; BP feature is the within-entity verified-vs-claimed exemplar at market-clearance scope.
What is the FDA Warning Letter to Whoop about Blood Pressure Insights?
On July 14, 2025, the FDA issued a Warning Letter to Whoop finding that the company's marketing of Blood Pressure Insights (BPI), launched May 2025 for Whoop MG, positioned the feature beyond the general-wellness scope that does not require 510(k) clearance for diagnostic claims. Whoop refused to remove the feature, defended BPI as wellness, and faced a subsequent class action lawsuit; as of May 2026 the matter remains unresolved. Whoop's market-first posture vs Oura's December 2025 BP study before marketing is the biometric cohort's sharpest verified-vs-claimed exemplar pair.
What is Ultrahuman Ring?
Ultrahuman Ring (Air / Pro) is a hardware + subscription-augmented smart ring biometric, positioned within the biometric cluster's ring sub-cohort as the market-access-redesigned archetype. Co-founder Vatsal Singhal (NOT Vatsal Kumar per Agent A Wave 2 correction). KEY EDITORIAL THROUGHLINE per Agent A biometric ingest: US market access blocked October 21, 2025 via Oura ITC '178 patent ruling (final determination effective August 2025); subsequently restored March 24, 2026 via Ring Pro unibody redesign cleared US Customs. Federal Circuit appeal pending; stay denied. AFib detection routes via FibriCheck third-party app integration (NOT native FDA-cleared). Editorial throughline: within-entity verified-vs-claimed (product + AI exist globally; US market access blocked + restored via patent-redesign), parallel to Apple SpO2 feature-scope disabled-then-restored saga.
What is Withings ScanWatch?
Withings is an independent French biometric wearable company; the ScanWatch line (ScanWatch + ScanWatch 2 + ScanWatch Nova) is the cohort's hybrid analog watch archetype. ECG cleared 2021 EU / OTC 2025 US; SpO2 monitoring across the line. Founded as Withings in France; acquired by Nokia 2016; bought back by founder Eric Carreel 2018; currently independent. Per DEPLOY's biometric cluster framework, Withings anchors the substantial-cleared-for-size archetype: hybrid mechanical-digital design distinct in cohort with cohort-mature peer-reviewed validation depth.
What is Zepp Health?
[Zepp Health](https://registry.deploy.report/companies/zepp-health) (formerly Huami) is a Chinese-headquartered consumer biometric maker behind the [Amazfit](https://registry.deploy.report/models/amazfit) smartwatch + band product line. Per registry verification: company entity at /companies/zepp-health; Amazfit product line at /models/amazfit (line-level slug covering the broader Amazfit watch + band portfolio). Per general industry context (cap-flagged at primary-source verification depth): Zepp Health is publicly-traded (NYSE: ZEPP); operates Amazfit consumer biometric brand at consumer-retail pricing tier; positioned within the biometric cluster's smartwatch + band cohort alongside Apple Watch + Pixel Watch + Fitbit + Samsung Galaxy Watch + Garmin + Whoop. Per [DEPLOY's biometric cluster framework](/explainers/biometric): specific Zepp Health product feature claims + FDA clearance posture + commercial deployment scope + AI-substance tier + funding state operate at lower verification posture pending primary-source confirmation. Cohort positioning: Chinese-headquartered consumer biometric maker entry within the biometric cluster's smartwatch + band cohort with cap-flagged claim depth pending primary-source verification.
Adjacent reading
Closest related material from adjacent clusters
AI wearables
What is an AI wearable?
An AI wearable is a body-worn device whose primary value comes from AI inference on captured sensor input (voice, camera, biosensors) rather than from the wearable hardware itself. The category spans pins, pendants, glasses, and audio devices. As of mid-2026 DEPLOY tracks 7 entities with 3 distinct operational states: commercial active (Plaud NotePin, Friend Pendant, Bee Wearable, Meta Ray-Ban), pilot active (Rabbit r1), and commercial discontinued (Humane AI Pin, Limitless Pendant). The Big Tech acquires pattern is the editorial throughline: Humane to HP, Bee to Amazon, Limitless to Meta.
Read →
AI wearables
What does wearable AI do?
Wearable AI does six things at different verification depths per DEPLOY's framework: (1) visual Q&A on what the camera sees (Meta Ray-Ban Look-and-Ask; Rokid; Brilliant Labs; Solos GPT-4o); (2) live translation across languages (Meta + Rokid with offline mode + Solos); (3) capture & summarize voice + transcripts (Plaud; Friend; Bee; Omi pending registry); (4) ambient recall of conversations + context (Bee; Friend; Omi pending registry); (5) smartphone replacement promised but verified-as-failed (Humane discontinued; Rabbit r1 marketing-vs-shipped gap); (6) health monitoring (uncovered in current DEPLOY cohort; Oura, Apple Watch, Fitbit are canonical contenders DEPLOY hasn't yet registered). The canonical wearable AI question conflates 'what is marketed' with 'what is verified-shipped'; DEPLOY's verified-vs-claimed framework fixes the conflation.
Read →
AI wearables
What is the best AI wearable in 2026?
There is no single best AI wearable in 2026; the right pick depends on use case, AI substance tier, and maturity. Per DEPLOY's framework: for visual assistance + genuine cloud AI shipping at consumer-deployment scale, Meta Ray-Ban anchors the Western verified-commercial position and Rokid anchors the non-Western. For audio-first capture and recall, Plaud (capture) and Friend (ambient) operate genuine cloud AI at commercial active. For developer-accessible / open-source orientation, Brilliant Labs Frame + Halo. For pilot-stage multi-purpose with marketing-vs-shipped gap, Rabbit r1. For commercial-discontinued failure context, Humane AI Pin. Trade-press 'best of' listicles collapse the axes; the right pick differs by buyer.
Read →